A recent pan-cancer analysis comparing CHD1L expression in normal and tumor tissues suggests its overexpression may approach 100% in several cancers, including thyroid, colorectal, stomach, head and neck, prostate, ovarian, and skin cancers [8] (Table 1). The gene discussed is CHD1L; the disease is neoplasm.